Status:
COMPLETED
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
Lead Sponsor:
Alhasan Mujtaba Abdul-Wahid
Collaborating Sponsors:
Ministry of Health-Basra Health Directorate-Al-Sader Teaching Hospital
Conditions:
Acute Kidney Injury
IHD
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
an interventional study to measure the possible effects of spironolactone ( an aldosterone antagonist) on the incidence of acute kidney injury after coronary angiography
Eligibility Criteria
Inclusion
- patients admitted to angiography unit
- over 18
- informed consent
Exclusion
- acute renal failure before 7 days
- spironolactone contraindications
- hyperkalemia (S.K. \>5.5 mEq/L)
- documented tumor
- actively taking NSAIDs, Ciclosporin, Cisplatin,
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 4 2018
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT03329443
Start Date
September 1 2017
End Date
September 4 2018
Last Update
September 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Sader Teaching Hospital
Basra, Iraq, 00964